Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL13262185 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19526092 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17858716 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12503065 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9143689 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2068 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2026-04-21 | — | — | US | claimed |
| US-20250049927-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | INTEROLIGO CORPORATION. (KR) | 2025-02-13 | — | — | US | claimed |
| EP-4450092-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | Interoligo Corporation (KR) | 2024-10-23 | — | — | EP | claimed |
| WO-2024081511-A2 | RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-04-18 | — | — | WO | claimed |
| US-20240100021-A1 | Combination Therapy Schedules to Treat Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-28 | — | — | US | claimed |
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS LLC | 2023-09-14 | — | — | US | claimed |
| WO-2023113243-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | 인터올리고 주식회사 | 2023-06-22 | — | — | WO | claimed |
| EP-4171552-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | Les Laboratoires Servier (FR) | 2023-05-03 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| US-20230049618-A1 | TUMOR SPECIFIC ANTIBODY CONJUGATES AND USES THEREFOR | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2023-02-16 | — | — | US | claimed |
| EP-0630905-B1 | Process for selectively isolating beta-2'-deoxy-2',2'-difluorocytidine or its salts | LILLY CO ELI (US) | 1999-05-06 | — | — | EP | claimed |
| US-5869461-A | Reducing toxicity associated with the administration of conventional ''D'' nucleoside drugs such as AZT, by coadministering ''L'' nucleoside compounds such as Beta L-2',3'-dideoxycytidine; AIDS | YALE UNIVERSITY (US) | 1999-02-09 | — | — | US | claimed |
| US-5776488-A | PHOSPHOLIPID, WATER SOLUBILE 2'-DEOXYCYTIDINE, STEROL, STEARYLAMINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-07-07 | — | — | US | claimed |
| US-5756478-A | Treating cancer while reducing toxicity associated with the administration of conventional ''D'' nucleoside drugs such as AZT, by coadministering ''L'' nucleoside compounds such as Beta-L-2',3'-dideoxy-2',3'-didehydrocytidine; AIDS | YALE UNIVERSITY (US) | 1998-05-26 | — | — | US | claimed |
| EP-0750910-A1 | LIPOSOME PREPARATION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-01-02 | — | — | EP | claimed |
| WO-1996028170-A1 | REDUCED TOXICITY COMPOSITIONS AND METHODS FOR TREATING HIV INFECTIONS | YALE UNIVERSITY (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0630905-A1 | Process for selectively isolating bêta-2'-deoxy-2',2'-difluorocytidine or its salts | ELI LILLY AND COMPANY (US) | 1994-12-28 | — | — | EP | claimed |
| US-5223608-A | Process for and intermediates of 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1993-06-29 | — | — | US | claimed |
| EP-0376518-A1 | Phospholipid nucleosides | ELI LILLY AND COMPANY (US) | 1990-07-04 | — | — | EP | claimed |
| EP-0306190-A2 | Improvements in or relating to 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1989-03-08 | — | — | EP | claimed |